Navigation Links
Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
Date:6/13/2010

UNION CITY, Calif., June 11 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has received notification from the U.S. Food & Drug Administration (FDA) that the PDUFA date for Questcor's supplemental new drug application (sNDA) to approve Acthar for the treatment of infantile spasms (IS) has been extended to September 11, 2010.  The FDA extended the PDUFA date in order to review information regarding labeling and potential post-approval commitments that they solicited from Questcor. This follows the May 6, 2010 votes by the Advisory Committee to the Division of Peripheral and Central Nervous System Drugs of the FDA which indicated support for approval of this new Acthar indication.  

"We look forward to working with the FDA over the next few months in order to finalize these critical elements," said Don M. Bailey, President and CEO of Questcor.

Investors should note that there can be no assurance that the FDA will approve this sNDA by September 11, 2010, or thereafter.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
2. Trading Halted Today in Questcor Pharmaceuticals Common Stock
3. Questcor to Discuss Results From FDA Panel Meeting
4. Questcor Reports Solid Fourth Quarter Results
5. Mylan Receives Approval for Generic Version of Neurontin® Tablets
6. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
7. Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension
8. Amedica® Receives Patent for Hip Implant Using Monoblock Ceramic Technology
9. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
10. PolyGel® Receives SADMERC Approval for L-Code L0627 for New ThermoActive™ Plus Cold & Hot Compression Lumbar Orthosis
11. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... G-CON Manufacturing, ... Miniature, and Modular (PCMM) collaboration with Pfizer and GEA by designing and building ... The new PODs will provide tablet coating capability in the existing line at ...
(Date:9/25/2017)... ... 25, 2017 , ... Lean Management techniques applied to the ... First-Defect-Stop for laboratory weighing is designed to help laboratory personnel strengthen lab ... consequences on downstream processes. , If a problem is detected, the "First-Defect-Stop" procedure ...
(Date:9/25/2017)... MI (PRWEB) , ... September 25, 2017 , ... The ... pallet solution. It is as simple as scanning the bar code of the ... is sent to a secure internet cloud where violations are automatically generated and exception ...
(Date:9/25/2017)... Korea (PRWEB) , ... September 25, 2017 , ... Earlypicker ... looking for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping ... for a company that’s already well-known for the great offerings that allow Koreans everywhere ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a tender and relatable ... with the others. “Grandpa's Visit” is the creation of published author, Beverly Brumfield, gifted ... much like the character in her book. She shares, “Mr. Rice is struggling to ...
Breaking Medicine News(10 mins):